GZBL(SZ:002424)2022-12-08 09:18Group 1: Drug Development Progress - The company successfully completed all preclinical studies for the new drug Tefentaf (originally Y101) and received clinical trial approvals for both the raw material and formulation on December 20, 2013, and January 21, 2014, respectively [3] - A technical development contract was signed with Beijing Bonoway Pharmaceutical Technology Development Co., Ltd. on March 17, 2014, to conduct Phase I clinical trials for Tefentaf [3] - A clinical research kickoff meeting for Tefentaf was held on August 15, 2014, with multiple institutions participating [3] Group 2: Clinical Research Findings - Preliminary studies indicated that Tefentaf demonstrated good antiviral effects and efficacy against drug-resistant virus strains [4] - The impurity control for Tefentaf was maintained within 1.5 ‰ [4] - Initial human studies for the drug showed significant blood sugar reduction effects, with statistical differences in fasting blood sugar compared to baseline (p < 0.01) [6] Group 3: Other Drug Developments - The company reported significant progress on the sugar-lowering capsule, which showed notable effects on glucose and lipid metabolism, and improved microvascular complications related to diabetes [5] - The capsule's acute toxicity was found to be minimal, and it received clinical trial approval from the Guizhou Provincial Food and Drug Administration [5] Group 4: Hospital Development and Strategic Focus - The company adjusted the implementation location and progress of the diabetes specialty hospital project due to various factors, with plans for trial operations by the end of August 2014 [6] - The company aims to enhance its basic drug market efforts, focusing on exclusive products and improving sales team capabilities [7] - Ongoing efforts include optimizing management systems and enhancing research and development for key projects [7][8]